Analyst Ratings For La Jolla Pharmaceutical (NASDAQ:LJPC)
Today, Chardan Capital raised its price target on La Jolla Pharmaceutical (NASDAQ:LJPC) to $100.00 per share.
Some recent analyst ratings include
- 12/22/2017-Cowen Reiterated Rating of Buy.
- 12/22/2017-JPMorgan Chase & Co. Reiterated Rating of Sell.
- 10/3/2017-Jefferies Group Reiterated Rating of Buy.
- 4/30/2017-Noble Financial Reiterated Rating of Buy.
- On 12/29/2018 Laura L Douglass, Director, sold 10,000 with an average share price of $32.32 per share and the total transaction amounting to $323,200.00.
- On 12/27/2018 Jennifer Carver, COO, bought 1,000 with an average share price of $33.22 per share and the total transaction amounting to $33,220.00.
- On 12/29/2017 Laura L Douglass, Director, sold 10,000 with an average share price of $32.32 per share and the total transaction amounting to $323,200.00.
- On 12/27/2017 Jennifer Carver, COO, bought 1,000 with an average share price of $33.22 per share and the total transaction amounting to $33,220.00.
- On 3/23/2017 Kevin C Tang, Director, bought 149,254 with an average share price of $33.50 per share and the total transaction amounting to $5,000,009.00.
- On 3/3/2017 Dennis Mulroy, CFO, bought 500 with an average share price of $33.95 per share and the total transaction amounting to $16,975.00.
- On 3/3/2017 George F Tidmarsh, CEO, bought 3,000 with an average share price of $34.17 per share and the total transaction amounting to $102,510.00.
Recent Trading Activity for La Jolla Pharmaceutical (NASDAQ:LJPC)
Shares of La Jolla Pharmaceutical closed the previous trading session at 34.61 up +1.54 4.66% with 34.91999816894531 shares trading hands.